InvestmentJun 10, 2026, 07:31 AM
CervoMed Secures $10.5M Private Placement; Extends Runway to Q2 2027
AI Summary
CervoMed Inc. announced a definitive securities purchase agreement for a private placement, anticipating upfront gross proceeds of approximately $10.5 million. This financing, supported by leading institutional healthcare investors and insiders, is expected to extend the company's cash runway into the second quarter of 2027. The funds will primarily support the pursuit of a strategic partnership to advance neflamapimod into Phase 3 development for dementia with Lewy bodies (DLB) and progress other pipeline indications, including nonfluent variant PPA and ALS programs. The company also provided updates on its strategic plan and upcoming clinical milestones for neflamapimod.
Key Highlights
- CervoMed secured approximately $10.5 million in upfront gross proceeds from a private placement.
- The financing extends the company's anticipated cash runway into the second quarter of 2027.
- The private placement included substantial participation from insiders and leading institutional healthcare investors.
- The company sold 3,360,377 units, with common stock units priced at $3.14 and pre-funded warrant units at $3.139.
- Series B warrants have an exercise price of $3.32 and expire on June 11, 2031.
- Series C warrants have an exercise price of $3.14 and expire on June 11, 2027.
- Anticipated additional gross proceeds of approximately $21.7 million if Series B and C warrants are fully exercised.
- Anticipated 24-week clinical data from nfvPPA Phase 2a trial in Q1 2027 and EXPERTS-ALS Phase 2a trial initiation in Q4 2026.
Price Impact
More from CRVO